This Article Full Text (PDF) All Versions of this Article: 1352458509107017v1 15/11/1271    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Festa, E. D Articles by Cadavid, D. PubMed PubMed Citation Articles by Festa, E. D Articles by Cadavid, D. Social Bookmarking                         What's this?

Serum levels of CXCL13 are elevated in active multiple sclerosis

UMDNJ-New Jersey Medical School, Newark, NJ, USA

Karolina Hankiewicz

Hospital Clini, Barcelona, Spain

Soyeon Kim

Department of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School, Newark, NJ, USA

Joan Skurnick

Department of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School, Newark, NJ, USA

Leo J Wolansky

Department of Radiology, UMDNJ-New Jersey Medical School, Newark, NJ, USA

Stuart D Cook

Department of Neurology and Neuroscience, UMDNJ-New Jersey Medical School, Newark, NJ, USA

Diego Cadavid

Department of Neurology and Neuroscience, UMDNJ-New Jersey Medical School, Newark, NJ, USA, cadavidi{at}umdnj.edu

There is increasing recognition of the important role that B cells play in the pathogenesis of multiple sclerosis (MS). Recently it was reported that the B cell chemokine CXCL13 is elevated in MS serum and cerebrospinal fluid. Here we study whether serum levels of CXCL13 are associated with active MS. We measured serum levels of CXCL13 by enzyme-linked immunosorbent assay in 74 patients with relapsing MS randomized to interferon beta 1b or glatiramer acetate and examined with monthly 3 T brain MRI scans optimized for detection of gadolinium-enhancement for up to 2 years. The median (range) serum levels of CXCL13 pre-treatment were 40 (3—171) pg/ml. Serum levels of CXCL13 were significantly higher at times of active brain MRI scans (p < 0.01). Furthermore, serum levels were higher in patients who never reached MRI remission compared with those in complete (p < 0.01) or partial (p = 0.01) remission. There was a significant positive correlation between the pattern of serum levels of CXCL13 and MRI activity during the first (r = 0.33, p < 0.05) and the full 2 years (r = 0.35, p < 0.01) of the study. Treatment with interferon beta 1b or glatiramer acetate did not affect serum CXCL13. We conclude that the serum levels of the B cell chemokine CXCL13 are associated with active MS.

Key Words: multiple sclerosis • brain • MRI • CXCL13 • biomarkers

This version was published on November 1, 2009

Multiple Sclerosis, Vol. 15, No. 11, 1271-1279 (2009)
DOI: 10.1177/1352458509107017


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?